FDA to Ease Copycat Drug Rules
The US Food and Drug Administration (FDA) announced it will relax rules for approving low-cost versions of high-priced medications, speeding access to cheaper alternatives.
Developers of biosimilars, near-identical copies of biologic drugs, will no longer need clinical trials to prove effectiveness.
- Biosimilars are used to treat conditions like cancer, diabetes, and autoimmune diseases.
- Examples of biosimilars include versions of Herceptin, Lantus, and Humira.
The FDA's decision affects biosimilars, medicines that are near-identical copies of biologic drugs made from living cells.
Author's summary: FDA eases biosimilar rules for cheaper drugs.
More News
- Police officer accused of breaching behaviour standards
- The legitimacy trap: How international institutions sustain the Houthis' hold on Yemen
- Hot Stocks: True North Copper, Trigg Minerals, 29Metals - Sharecafe
- Somalia’s eVisa Fiasco: Bureaucracy Without Legitimacy - WardheerNews
- You Will Be Found: Dear Evan Hansen Musical Left Me In Tears
- A Farmer's Wife: The Glue That Holds Harvest Together